What is Sensydia?
Sensydia specializes in the development and deployment of its innovative Cardiac Performance System (CPS). This technology facilitates rapid, non-invasive assessment of key hemodynamic metrics, designed for use in hospitals and cardiology offices. The CPS platform empowers healthcare professionals to make more informed decisions regarding patient care, aiming to improve outcomes for individuals with heart failure and other critical cardiovascular conditions. By simplifying the acquisition of advanced hemodynamic measures, Sensydia seeks to enhance patient care while simultaneously reducing healthcare costs and hospital readmissions, making vital hemodynamic measurements more accessible.
How much funding has Sensydia raised?
Sensydia has raised a total of $11M across 2 funding rounds:
Other Financing Round
$8M
Grant
$3M
Other Financing Round (2023): $8M with participation from Colle Capital and Frontier Venture Capital
Grant (2023): $3M led by National Heart, Lung, and Blood Institute
Key Investors in Sensydia
Colle Capital
Colle Capital Partners is a global early-stage technology venture fund that focuses on investing in innovative entrepreneurs and their bold ideas, emphasizing data-driven investment management and agility.
Frontier Venture Capital
Frontier Venture Capital invests in early-stage technology companies across the United States, supporting entrepreneurs with innovative technologies that enhance joy, well-being, safety, and productivity.
National Heart, Lung, and Blood Institute
The National Heart, Lung, and Blood Institute provides global leadership for research, training, and education programs aimed at preventing and treating heart, lung, and blood disorders.
What's next for Sensydia?
With the recent major strategic investment and overall enterprise-level funding, Sensydia is poised for significant expansion and further development of its Cardiac Performance System. The company's focus on improving patient outcomes and reducing healthcare costs through accessible hemodynamic assessment positions it for substantial growth in the critical care and cardiology markets. Future strategic initiatives are likely to involve scaling operations, enhancing the CPS platform's capabilities, and broadening its market reach to healthcare providers globally. This capital infusion will be instrumental in accelerating Sensydia's mission to make advanced cardiovascular monitoring a standard of care.
See full Sensydia company page
